CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer

被引：77

作者：

Agrawal, Satish ^{[1
,2
]}

Dwivedi, Monika ^{[1
]}

Ahmad, Hafsa ^{[1
]}

Chadchan, Sangappa Basanna ^{[3
]}

Arya, Abhishek ^{[1
,2
]}

Sikandar, Roshan ^{[1
,4
]}

Kaushik, Shweta ^{[2
,5
]}

Mitra, Kalyan ^{[6
]}

Kumar, Rajesh ^{[3
]}

Dwivedi, Anil Kumar ^{[1
]}

机构：

[1] CSIR Cent Drug Res Inst, Pharmaceut Div, Lucknow, Uttar Pradesh, India

[2] Acad Sci & Innovat Res AcSIR, Madras, Tamil Nadu, India

[3] CSIR Cent Drug Res Inst, Endocrinol Div, Lucknow, Uttar Pradesh, India

[4] Natl Inst Pharmaceut Educ & Res, Raebareli, UP, India

[5] CSIR Drug Res Inst, Div Biochem, Lucknow, Uttar Pradesh, India

[6] CSIR Drug Res Inst, Electron Microscopy Unit, Lucknow, Uttar Pradesh, India

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2018年 / 14卷 / 02期

关键词：

Lapatinib; Tykerb; Nanocrystals; Hyaluronic acid; Triple-negative breast cancer; STEM-LIKE CELLS; DRUG NANOCRYSTALS; KINASE INHIBITOR; LUNG METASTASIS; THERAPY; NANOPARTICLES; PACLITAXEL; DELIVERY; TUMOR; THERAPEUTICS;

D O I：

10.1016/j.nano.2017.10.010

中图分类号：

TB3 [工程材料学];

学科分类号：

082905 [生物质能源与材料];

摘要：

Lapatinib (LPT) is an orally administered drug for the treatment of metastatic breast cancer. For expanding its therapeutic horizon, we have prepared its nanocrystals (LPT-NCs) that were subsequently coated with hyaluronic acid (HA) to produce LPT-HA-NCs. The detailed in-vitro and in-vivo investigation of LPT-HA-NCs showed the superior anticancer activity due to active targeting to CD44 receptors than the counterparts LPT-NCs and free LPT. In the triple negative 4T1 cells induced breast tumor bearing female Balb/C mice; LPT-HA-NCs treatment caused significant retardation of tumor growth and overall increase in animal survival probability because of their higher tumor localization, increased residence time. Our findings clearly suggest that HA coated LPT-NCs formulation enhances the activity of LPT against triple negative breast cancer. It exhibited magnificent therapeutic outcome at low dose thus presenting a strategy to reduce dose administrations and minimize dose related toxicity. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：327 / 337

页数：11

共 46 条

[1]

PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy [J].

Agrawal, Satish ;

Ahmad, Hafsa ;

Dwivedi, Monika ;

Shukla, Mahendra ;

Arya, Abhishek ;

Sharma, Komal ;

Lal, Jawahar ;

Dwivedi, Anil Kumar .

NANOMEDICINE, 2016, 11 (16) :2147-2169

[2]

Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations [J].

Al-Ghananeem, Abeer M. ;

Malkawi, Ahmad H. ;

Muammer, Yahya M. ;

Balko, Justin M. ;

Black, Esther P. ;

Mourad, Walid ;

Romond, Edward .

AAPS PHARMSCITECH, 2009, 10 (02) :410-417

[3]

Co-delivery of hesperetin enhanced bicalutamide induced apoptosis by exploiting mitochondrial membrane potential via polymeric nanoparticles in a PC-3 cell line [J].

Arya, Abhishek ;

Khandelwal, Kiran ;

Ahmad, Hafsa ;

Laxman, Tulsankar Sachin ;

Sharma, Komal ;

Mittapelly, Naresh ;

Agrawal, Satish ;

Bhatta, Rabi S. ;

Dwivedi, Anil K. .

RSC ADVANCES, 2016, 6 (07) :5925-5935

[4]

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects [J].

Bence, AK ;

Anderson, EB ;

Halepota, MA ;

Doukas, MA ;

DeSimone, PA ;

Davis, GA ;

Smith, DA ;

Koch, KM ;

Stead, AG ;

Mangum, S ;

Bowen, CJ ;

Spector, NL ;

Hsieh, S ;

Adams, VR .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (01) :39-49

[5]

Cationic nanoparticles for cancer therapy [J].

Bilensoy, Erem .

EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (07) :795-809

[6]

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy? [J].

Budha, N. R. ;

Frymoyer, A. ;

Smelick, G. S. ;

Jin, J. Y. ;

Yago, M. R. ;

Dresser, M. J. ;

Holden, S. N. ;

Benet, L. Z. ;

Ware, J. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (02) :203-213

[7]

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies [J].

Burris, Howard A., III ;

Taylor, Charles W. ;

Jones, Suzanne F. ;

Koch, Kevin M. ;

Versola, Melissa J. ;

Arya, Niki ;

Fleming, Ronald A. ;

Smith, Deborah A. ;

Pandite, Lini ;

Spector, Neil ;

Wilding, George .

CLINICAL CANCER RESEARCH, 2009, 15 (21) :6702-6708

[8]

Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity [J].

Castellino, Stephen ;

O'Mara, Michael ;

Koch, Kevin ;

Borts, David J. ;

Bowers, Gary D. ;

MacLauchlin, Christopher .

DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) :139-150

[9]

Nanoparticle therapeutics: an emerging treatment modality for cancer [J].

Davis, Mark E. ;

Chen, Zhuo ;

Shin, Dong M. .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) :771-782

[10]

Assessing the in Vivo Efficacy of Doxorubicin Loaded Hyaluronan Nanoparticles [J].

El-Dakdouki, Mohammad H. ;

Xia, Jingguang ;

Zhu, David C. ;

Kavunja, Herbert ;

Grieshaber, Jessica ;

O'Reilly, Sandra ;

McCormick, J. Justin ;

Huang, Xuefei .

ACS APPLIED MATERIALS & INTERFACES, 2014, 6 (01) :697-705

← 1 2 3 4 5 →